Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Procept BioRobotics Corp. PRCT

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$308.1M
▲ 37.2% YoY
$-95.6M
$-58.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). As of December 31, 2025, it had an install base of 912 AquaBeam Robotic Systems and HYDROS Robotic Systems globally, including 718 in the United States. As of December 31, 2025, it had 888 employees. It directly manufactures its robotic systems, the handpiece and other accessories at its facility in San Jose, California. Its first-generation AquaBeam Robotic System received De Novo FDA approval in December 2017.

Written from the business description in PROCEPT BioRobotics Corp's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 308.1M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 308.1 · Net income -95.6
150M300M-50M-100M
202020232025
Compound annual growth
+60.1%
+109.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +109.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−31 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -33.7% · Net -31.0%
-200%-400%-600%
202020222025
ROE
FY2025 · ROE -24.9%
-20%-40%
202020222025
Three returns, three denominators.

Each USD of equity lost 25 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -58.3
-50M-100M
202020222025

Total assetsUSD 508.1M
EquityUSD 365.9M
CashUSD 286.5M
Gross debtUSD 51.6M
Net debtUSD -234.9M
Current ratio6.85×

The company holds more cash than debt.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PRCT, 6-year financial record
Metric 202520242023202220212020
Revenue $B0.30.20.10.10.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.0
Income tax $B0.00.00.00.00.00.0
Net income $B−0.1−0.1−0.1−0.1−0.1−0.1
Free cash flow $B−0.1−0.1−0.1−0.1−0.1−0.0
EPS, diluted $−1.72−1.75−2.24−1.96−3.63−14.47
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE %−24.9−26.8−44.3−37.6——
Shares out B0.060.050.05◌0.040.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 30 reconciliationsAUDITED

Reconciled in 6 of the 6 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 13 checks were skipped: EPS is not tagged before 2020. 13 checks were skipped: revenue is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2020

Share this section

Download image